Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO)

Medical Hypotheses

Volumn 69, Issue 6, 2007, Pages 1200-1204

  Burk, R ^a  

^a Burk Labs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; ARTICLE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; DRUG COST; DRUG SAFETY; ERYTHROPOIESIS; HEADACHE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; NAUSEA; OXYGEN BREATHING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; TACHYCARDIA; VOMITING;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; FEMALE; HUMANS; MEDICAL ONCOLOGY; MODELS, ECONOMIC; MODELS, THEORETICAL; NEOPLASMS; OXYGEN; OXYGEN INHALATION THERAPY; RESPIRATION;

EID: 35448979980     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.03.015     Document Type: Article

References (25)

1. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 Suppl. 7A (2004) 11S-26S
2. Kirshner J., Hatch M., Hennessy D.D., Fridman M., and Tannous R.E. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 9 1 (2004) 25-32
3. Macdougall I.C. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl 80 (2002) 55-61
4. Lefebvre P., Gosselin A., McKenzie R.S., Mody S.H., Piech C.T., and Duh M.S. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 22 9 (2006) 1623-1631
5. Steensma D.P., and Loprinzi C.L. Erythropoietin use in cancer patients: a matter of life and death?. J Clin Oncol 23 25 (2005) 5865-5868
6. Counterfeit Procrit. FDA Consum. 2003; 37(3):5.
7. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18 3 (2005) 473-480
8. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 9392 (2003) 1255-1260
9. Leyland-Jones B. BEST Investigators and Study Group Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 8 (2003) 459-460
10. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 29 (2006) 4708-4713
11. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 20 (2006) 2085-2098
12. McMahon F.G., Vargas R., Ryan M., Jain A.K., Abels R.I., Perry B., et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76 9 (1990) 1718-1722
13. Dunlop E.A., Percy M.J., Boland M.P., Maxwell A.P., and Lappin T.R. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3 1-2 (2006) 94-100
14. Osterborg A., Aapro M., Cornes P., Haselbeck A., Hayward C.R., and Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43 3 (2007) 510-519
15. Coleman T., and Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?. Crit Care 8 5 (2004) 337-341
16. Wilber R.L. Current trends in altitude training. Sports Med 31 4 (2001) 249-265
17. Balestra C., Germonpre P., Poortmans J.R., and Marroni A. Serum erythropoietin levels in healthy humans after a short period of normobaric and hyperbaric oxygen breathing: the "normobaric oxygen paradox. J Appl Physiol 100 2 (2006) 512-518
18. Carpagnano G.E., Kharitonov S.A., Foschino-Barbaro M.P., Resta O., Gramiccioni E., and Barnes P.J. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 59 12 (2004) 1016-1019
19. Milone S.D., Newton G.E., and Parker J.D. Hemodynamic and biochemical effects of 100% oxygen breathing in humans. Can J Physiol Pharmacol 77 2 (1999) 124-130
20. Vina J., Servera E., Asensi M., Sastre J., Pallardo F.V., Ferrero J.A., et al. Exercise causes blood glutathione oxidation in chronic obstructive pulmonary disease: prevention by O2 therapy. J Appl Physiol 81 5 (1996) 2198-2202
21. Berglund B., Gennser M., Ornhagen H., Ostberg C., and Wide L. Erythropoietin concentrations during 10 days of normobaric hypoxia under controlled environmental circumstances. Acta Physiol Scand 174 3 (2002) 225-229
22. Ng T., Marx G., Littlewood T., and Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 79 933 (2003) 367-376
23. Ross R.P., McCrea J.B., and Besarab A. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J 40 3 (1994) M880-M885
24. MacLeod J.N., Tetreault J.W., Lorschy K.A., and Gu D.N. Expression and bioactivity of recombinant canine erythropoietin. Am J Vet Res 59 9 (1998) 1144-1148
25. Sfacteria A., Mazzullo G., Bertani C., Calabro P., De Vico G., and Macri B. Erythropoietin receptor expression in canine mammary tumor: an immunohistochemical study. Vet Pathol 42 6 (2005) 837-840